...
首页> 外文期刊>The FASEB Journal >Adjunctive β2-agonist treatment reduces glycogen independently of receptor-mediated acid α-glucosidase uptake in the limb muscles of mice with Pompe disease
【24h】

Adjunctive β2-agonist treatment reduces glycogen independently of receptor-mediated acid α-glucosidase uptake in the limb muscles of mice with Pompe disease

机译:辅助β2-激动剂处理可减少与Pompe疾病的小鼠肢体肌肉中的受体介导的酸α-葡糖苷酶摄取的糖原

获取原文
           

摘要

Enzyme or gene replacement therapy with acid α-glucosidase (GAA) has achieved only partial efficacy in Pompe disease. We evaluated the effect of adjunctive clenbuterol treatment on cation-independent mannose-6-phosphate receptor (CI-MPR)-mediated uptake and intracellular trafficking of GAA during muscle-specific GAA expression with an adeno-associated virus (AAV) vector in GAA-knockout (KO) mice. Clenbuterol, which increases expression of CI-MPR in muscle, was administered with the AAV vector. This combination therapy increased latency during rotarod and wirehang testing at 12 wk, in comparison with vector alone. The mean urinary glucose tetrasaccharide (Glc4), a urinary biomarker, was lower in GAA-KO mice following combination therapy, compared with vector alone. Similarly, glycogen content was lower in cardiac and skeletal muscle following 12 wk of combination therapy in heart, quadriceps, diaphragm, and soleus, compared with vector alone. These data suggested that clenbuterol treatment enhanced trafficking of GAA to lysosomes, given that GAA was expressed within myofibers. The integral role of CI-MPR was demonstrated by the lack of effectiveness from clenbuterol in GAA-KO mice that lacked CI-MPR in muscle, where it failed to reverse the high glycogen content of the heart and diaphragm or impaired wirehang performance. However, the glycogen content of skeletal muscle was reduced by the addition of clenbuterol in the absence of CI-MPR, as was lysosomal vacuolation, which correlated with increased AKT signaling. In summary, β2-agonist treatment enhanced CI-MPR-mediated uptake and trafficking of GAA in mice with Pompe disease, and a similarly enhanced benefit might be expected in other lysosomal storage disorders.—Farah, B. L., Madden, L., Li, S., Nance, S., Bird, A., Bursac, N., Yen, P. M., Young, S. P., Koeberl, D. D. Adjunctive β2-agonist treatment reduces glycogen independently of receptor-mediated acid α-glucosidase uptake in the limb muscles of mice with Pompe disease.
机译:酶或基因替代疗法与酸α-葡糖苷酶(GAA)在Pompe疾病中仅实现了部分疗效。我们评估了辅助Clenbuterol治疗对阳离子甘露糖-6-磷酸盐受体(CI-MPR)介断的摄取和细胞内运输Gaa的疗法Gaa在GaA中的腺相关病毒(AAV)载体中的影响和细胞内运输Gaa的影响敲除(Ko)小鼠。将CI-MPR在肌肉中的表达增加,用AAV载体给予Clenbuterol。与单独的载体相比,这种组合疗法在12WK的旋转盘和Liebhang检测期间增加潜伏期。与单独的载体相比,平均尿葡萄糖四糖(Glc4),尿生物标志物在GaA-Ko小鼠中较低。类似地,在心脏病,Quadriceps,隔膜和单独的12周后,心脏和骨骼肌中的糖原含量较低,与单独的载体相比。这些数据表明,鉴于Gaa在肌纤维中表达,Clenbuterol治疗增强了Gaa对溶酶体的贩运。 CI-MPR的积分作用是通过克伦甲醇中缺乏肌肉中缺乏CI-MPR的含量缺乏有效作用,在那里未能逆转心脏和膜片的高糖原含量或WILEHANG性能受损。然而,在没有CI-MPR的情况下,通过添加C1MPR的克伦甲醇,骨肉肌肉的糖原含量降低,与溶酶体真空相比,溶酶体真空与增加的Akt信号传导相关。总之,β2-激动剂治疗增强的CI-MPR介导的CI-MPR介导的摄取和贩运GAA在小鼠中,在其他溶酶体储存障碍中可能预期同样增强的益处。 - 法拉,BL,MADDEN,L.,LI, S.,NANCE,S.,鸟,A。,Bursac,N.,Yen,PM,Young,SP,Koeberl,DD辅助β2-激动剂治疗可在肢体肌肉中独立于受体介导的酸性α-葡糖苷酶摄取而减少糖原患有Pompe疾病的小鼠。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号